The newly-approved combination drug, relugolixestradiolnorethisterone (Ryeqo), represents a significant advancement in treating endometriosis for about 1,000 women annually in England. Licensed by NICE, this first long-term daily pill offers advantages over traditional injectable therapies by allowing at-home administration and quicker symptom relief. Endometriosis affects 1.5 million women in the UK, often misdiagnosed for years. The new treatment addresses longstanding concerns about accessibility while providing effective relief, particularly for patients whose previous treatments have failed. It delivers necessary hormonal therapy while minimizing the risks of exacerbating symptoms during initial stages.
This new treatment marks a potential step-change in how we manage endometriosis, putting control back in patients' hands while ensuring value for the taxpayer. Instead of travelling to clinics for injections, there is now a daily tablet that can be taken at home, providing a more convenient and effective alternative.
The combination drug, relugolixestradiolnorethisterone, is the first long-term daily pill licensed to treat endometriosis, helping around 1,000 women yearly in England.
Endometriosis affects around 1.5 million women in the UK, but typical diagnosis takes nine years, highlighting the importance of effective and accessible treatment solutions.
New evidence provided by Gedeon Richter satisfactorily addressed previous questions about the drug's effectiveness and value for money, leading to its approval by Nice.
Collection
[
|
...
]